16. 11.14 11:26 Close share menu Merck Announces Positive Study Investigating the Use of KEYTRUDA (pembrolizumab) Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma Source FinanzNachrichten.de Close share menu